Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Pre-Market Trading 11-22 05:58:06 EST

6.79

+0.25

+3.82%

High6.89	Low6.37	Vol151.16K
Open6.53	D1 Closing6.54	Amplitude8.00%
Mkt Cap93.68M	Tradable Cap74.57M	Total Shares13.80M
T/O1.01M	T/O Rate1.38%	Tradable Shares10.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":6.79,"timestamp":1732222800000,"preClose":6.54,"halted":0,"volume":151156,"delay":0,"floatShares":10982300,"shares":13797242,"eps":-3.972968,"marketStatus":"Pre-Market Trading","change":0.25,"latestTime":"11-22 05:58:06 EST","open":6.53,"high":6.89,"low":6.367,"amount":1011172.572976,"amplitude":0.079969,"askPrice":7.65,"askSize":100,"bidPrice":6.21,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.972968,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":6.79,"postHourTrading":{"tag":"盘后","latestPrice":6.79,"preClose":6.79,"latestTime":"19:21 EST","volume":47,"amount":323.91,"timestamp":1732234916393},"volumeRatio":0.7317132208907116,"impliedVol":1.0678,"impliedVolPercentile":0.1203},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2483551327","title":"Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2483551327","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483551327?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:15","pubTimestamp":1731672911,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on ANVS stock, giving a Buy rating on November 11. Sumant Kulkarni ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-buy-rating-on-annovis-bio-amid-regulatory-alignment-and-growth-potential-in-alzheimers-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-buy-rating-on-annovis-bio-amid-regulatory-alignment-and-growth-potential-in-alzheimers-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2482270152","title":"Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270152","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482270152?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  12, 2024   -- via IBN – Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease  and Parkinson’s disease , today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to speak at the National Institute on Aging  workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” This prestigious workshop, sponsored by the NIA and the National Institute of Neurological Disorders and Stroke , will be held on November 12-13, 2024, and accessible online for registered attendees. Presentation Details: Title: One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer's and Parkinson's Patients. A Potential Path for Lewy Body Dementia?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979097/0/en/Annovis-Invited-to-Present-at-National-Institute-on-Aging-Workshop-on-Dementia-with-Lewy-Bodies-DLB.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6M65.USD","IE00B7N09G41.SGD","LU1102505929.USD","LU0264410563.USD","PD","LU0345774631.USD","LU0348723411.USD","LU0240878834.USD","IBN","LU0531971678.HKD","LU0066902890.USD","SG9999004220.SGD","LU0828237940.HKD","BK4523","LU0205194284.USD","LU1868837722.USD","LU0143863198.USD","LU0345774391.USD","BK4585","IE00BYTNYM70.SGD","LU0240877869.USD","LU1169589451.USD","GRO","LU0164881194.USD","BK4535","LU1169590202.USD","LU0205193047.USD","LU0251143458.SGD","LU1102505762.USD","BK4023","BK4588","LU0143863784.USD","LU0823039010.USD","NHLD","LU0181495838.USD","BK4139","DLB","BK4548","LU0823038988.USD","LU1868838027.USD","BK4207","BK4097","LU1868837565.USD","ANVS"],"gpt_icon":0},{"id":"2482781569","title":"Annovis Bio GAAP EPS of -$0.97 misses by $0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2482781569","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482781569?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:14","pubTimestamp":1731330862,"startTime":"0","endTime":"0","summary":"Annovis Bio press release (NYSE:ANVS): Q3 GAAP EPS of -$0.97  misses by $0.58. As of November 8, 2024, Annovis had cash and cash equivalents of $13.6 million. The company has an adequate runway for all Phase 3 preparatory studies and for entering the pivotal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4274126-annovis-bio-gaap-eps-of-0_97-misses-0_58","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ANVS"],"gpt_icon":0},{"id":"2482789853","title":"Annovis Bio Q3 EPS $(0.97) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482789853","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482789853?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:06","pubTimestamp":1731330399,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.38) by 155.26 percent. This is a 40.49 percent increase over losses of $(1.63) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41876835/annovis-bio-q3-eps-0-97-misses-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Annovis Bio Q3 EPS $(0.97) Misses $(0.38) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2482485786","title":"Annovis Bio Reports Third Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482485786?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA7XBPYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2482786063","title":"Annovis Bio Reports Third Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786063?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  11, 2024  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a clinical-stage drug platform company developing novel therapies for neurodege","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978272/0/en/Annovis-Bio-Reports-Third-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","IE00B7N09G41.SGD","LU0181495838.USD","ANVS","LU0828237940.HKD","LU1868837565.USD","GRO","BK4535","BK4548","LU0143863198.USD","IE00B0JY6M65.USD","IE00BYTNYM70.SGD","LU0164881194.USD","LU0823039010.USD","SG9999004220.SGD","LU1102505929.USD","BK4207","LU1868837722.USD","LU1868838027.USD","BK4139","LU0143863784.USD","BK4588","LU0066902890.USD","LU0251143458.SGD","PD","BK4585","LU0531971678.HKD","LU1169590202.USD","LU1169589451.USD","LU0264410563.USD","BK4523","LU0823038988.USD","LU1102505762.USD","IBN"],"gpt_icon":0},{"id":"2482578558","title":"Annovis Bio Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482578558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482578558?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:39","pubTimestamp":1731328740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 07:39 ET (12:39 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2482805447","title":"Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482805447","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482805447?lang=en_us&edition=fundamental","pubTime":"2024-11-09 20:26","pubTimestamp":1731155169,"startTime":"0","endTime":"0","summary":"* Annovis Bio Inc    reported a quarterly adjusted loss of 97 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.63.  The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2481904837","title":"Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904837","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904837?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov. 07, 2024  -- via IBN --Annovis Bio Inc.  , a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease  and Parkinson’s disease , today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.\"We are thrilled to welcome Matthew Peterson to our team,\" said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. \"Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”\"I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company,\" said Dr. Peterson. \"I look forward","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nFPIV6UEv5MtRZH7nCVaFQ--~B/aD0xNTg7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9fc709677795ec8aacefdbb92bf7c00b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-appoints-matthew-peterson-130000124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0143863198.USD","LU0531971678.HKD","LU0828237940.HKD","BK4588","LU0143863784.USD","LU1102505929.USD","PD","IBN","LU0823039010.USD","SG9999004220.SGD","ANVS","BK4523","LU0181495838.USD","LU0251143458.SGD","LU0264410563.USD","BK4548","IE00B7N09G41.SGD","LU1169589451.USD","IE00B0JY6M65.USD","BK4139","LU0164881194.USD","BK4207","LU1868838027.USD","LU1169590202.USD","BK4535","BK4023","LU1868837565.USD","LU1102505762.USD","LU0066902890.USD","LU1868837722.USD","IE00BYTNYM70.SGD","LU0823038988.USD"],"gpt_icon":0},{"id":"2480158002","title":"Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480158002","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480158002?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:48","pubTimestamp":1730735301,"startTime":"0","endTime":"0","summary":"* Annovis Bio Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst estimate f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Annovis Bio Inc    expected to post a loss of 53 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2479051088","title":"Ibn Announces Latest Episode of the Biomedwire Podcast Featuring DR. Maria Maccecchini, CEO of Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2479051088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479051088?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA7JP7BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2479085148","title":"IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2479085148","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479085148?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Oct. 31, 2024  -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease  and Parkinson’s disease .In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration , which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.The latest installment of The BioMe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0264410563.USD","LU1102505762.USD","LU1868837722.USD","BK4585","LU0066902890.USD","LU1169589451.USD","IBN","LU0143863198.USD","LU0823039010.USD","BK4535","BK4588","DBP","LU0531971678.HKD","LU0828237940.HKD","LU0143863784.USD","BK4139","BK4548","IE00B7N09G41.SGD","LU0251143458.SGD","SG9999004220.SGD","LU1868837565.USD","LU0164881194.USD","BK4207","LU1868838027.USD","BK4023","LU1102505929.USD","ANVS","BK4523","LU0823038988.USD","LU1169590202.USD","LU0181495838.USD","PD","IE00B0JY6M65.USD","IE00BYTNYM70.SGD"],"gpt_icon":0},{"id":"2478195956","title":"Maxim Upgrades Annovis Bio to Buy From Hold, Price Target is $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2478195956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478195956?lang=en_us&edition=fundamental","pubTime":"2024-10-26 00:39","pubTimestamp":1729874340,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) has an average rating of outperform and price targets ranging from $21 to $72, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic researc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANVS"],"gpt_icon":0},{"id":"1124327651","title":"Top Calls on Wall Street | Apple Downgraded, Tesla Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=1124327651","media":"The Fly","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124327651?lang=en_us&edition=fundamental","pubTime":"2024-10-25 23:20","pubTimestamp":1729869600,"startTime":"0","endTime":"0","summary":"Tesla upgrade, Apple downgrade, Uber initiation among today's top calls on Wall StreetThe most talked about and market moving research calls around Wall Street are now in one place. Here are today's r","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://thefly.com/landingPageNews.php?id=4005716&headline=TSLA;TOL;APD;ANVS;DENN;AAPL;TMUS;BYON;KHC;BMY;UBER;LYFT;BLDR;APLS;REG-Apple-downgraded-Tesla-upgraded-Wall-Streets-top-analyst-calls&utm_source=https://thefly.com/&utm_medium=referral&utm_campaign=referral_traffic","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1649979459173","symbols":["BMY","BLDR","BYON","KHC","TOL","UBER","ANVS","AAPL","DENN","TMUS","APLS","TSLA","APD","REG","LYFT"],"gpt_icon":1},{"id":"2478981110","title":"Annovis Bio Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2478981110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478981110?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:21","pubTimestamp":1729858860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 08:21 ET (12:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2477574333","title":"Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2477574333","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477574333?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Oct.  22, 2024  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company developing transformative therapies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/22/2966877/0/en/Annovis-to-Highlight-Buntanetap-s-Alzheimer-s-Research-Progress-with-Presentations-at-CTAD-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0066902890.USD","BK4023","LU0264410563.USD","LU0143863784.USD","BK4097","SG9999004220.SGD","BK4523","IE00BYTNYM70.SGD","LU1102505929.USD","PRGS","LU1169590202.USD","LU1868837565.USD","LU0531971678.HKD","LU0828237940.HKD","BK4207","BK4548","BK4535","LU2065732104.USD","LU1169589451.USD","BK4588","LU1868838027.USD","IE00B0JY6M65.USD","CET","LU0251143458.SGD","BK4139","LU0181495838.USD","BK4585","IBN","PD","LU0143863198.USD","LU0823038988.USD","LU0823039010.USD","ANVS","IE00B7N09G41.SGD","LU1102505762.USD","LU0164881194.USD","LU1868837722.USD"],"gpt_icon":0},{"id":"2476456925","title":"Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2476456925","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476456925?lang=en_us&edition=fundamental","pubTime":"2024-10-18 04:29","pubTimestamp":1729196952,"startTime":"0","endTime":"0","summary":"Annovis plans to initiate two Phase 3 trials for Alzheimer's and file for Parkinson’s approval despite failing primary endpoints in the overall population.The company lacks sufficient funds, with only","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1818667823/image_1818667823.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1818667823/image_1818667823.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4727476-annovis-bio-funding-may-be-an-issue-for-announced-phase-3-trials","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2476530564","title":"Annovis Bio To Continue Alzheimer's Disease Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2476530564","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476530564?lang=en_us&edition=fundamental","pubTime":"2024-10-18 03:26","pubTimestamp":1729193180,"startTime":"0","endTime":"0","summary":"In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70% stock drop.The company plans to proceed with a phase 3 trial de","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286140964/image_1286140964.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286140964/image_1286140964.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4727452-annovis-bio-to-continue-alzheimers-disease-clinical-trials","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2476385170","title":"Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476385170","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476385170?lang=en_us&edition=fundamental","pubTime":"2024-10-17 22:52","pubTimestamp":1729176747,"startTime":"0","endTime":"0","summary":"Oct. 17, 2024 The market is enthusiastic to Annovis Bio, Inc.  and some say that they tackle Alzheimer's and Parkinson's in ways humanity has never achieved before. The company recently announced FDA clearance for Phase 3 trials of its lead Alzheimer's drug candidate, buntanetap.Buntanetap is reported to do well in Phase 2 trials and has indicated improvement in patients with Alzheimer. The FDA's action to allow the company to go to Phase 3 is a positive point to the fact that buntanetap may be an effective cure for this disease that ravages the lives of so many people.The future of Annovis Bio is wide open because its drug targets Alzheimer's and other neurodegenerative diseases that many people had. The approach of nanotechnology has the possibility of targeting many toxic proteins that cause Alzheimer's and Parkinson's indicating a better solution than the existing treatments.The stock price conveyed a staggering one-day increase of 14.54% on Wednesday but the year-to-date loss is s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VNg9csLLfXTixm_p8bX9Og--~B/aD0zMjt3PTMyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/620fa2e94498a9e4bd09f78907163fc2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VNg9csLLfXTixm_p8bX9Og--~B/aD0zMjt3PTMyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/620fa2e94498a9e4bd09f78907163fc2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-shows-promise-fda-145227742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2475969321","title":"Annovis Bio Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2475969321","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475969321?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:18","pubTimestamp":1729077480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2024 07:18 ET (11:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.2949},{"period":"3month","weight":-0.2993},{"period":"6month","weight":-0.0686},{"period":"1year","weight":0.0576},{"period":"ytd","weight":-0.6369}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001878},{"month":2,"riseRate":0.4,"avgChangeRate":0.208855},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008916},{"month":4,"riseRate":0.2,"avgChangeRate":-0.160489},{"month":5,"riseRate":0.6,"avgChangeRate":0.247553},{"month":6,"riseRate":0.6,"avgChangeRate":0.216567},{"month":7,"riseRate":0.6,"avgChangeRate":0.066217},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05366},{"month":9,"riseRate":0.4,"avgChangeRate":-0.049402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090551},{"month":11,"riseRate":0.6,"avgChangeRate":0.037886},{"month":12,"riseRate":0.5,"avgChangeRate":0.329002}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction